Royal London Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $32.1M | Buy |
753,076
+87,185
| +13% | +$4.73M | 0.06% | 251 |
|
|
2026
Q1 | $41.8M | Sell |
665,891
-7,360
| -1% | -$589K | 0.09% | 199 |
|
|
2025
Q4 | $64.2M | Sell |
673,251
-5,810
| -0.9% | -$570K | 0.14% | 145 |
|
|
2025
Q3 | $66.3M | Sell |
679,061
-10,746
| -2% | -$1.11M | 0.14% | 139 |
|
|
2025
Q2 | $74.1M | Sell |
689,807
-19,934
| -3% | -$2.02M | 0.17% | 117 |
|
|
2025
Q1 | $71.6M | Buy |
709,741
+77,280
| +12% | +$7.78M | 0.17% | 112 |
|
|
2024
Q4 | $56.5M | Sell |
632,461
-2,618
| -0.4% | -$230K | 0.14% | 133 |
|
|
2024
Q3 | $53.2M | Buy |
635,079
+22,525
| +4% | +$1.78M | 0.13% | 142 |
|
|
2024
Q2 | $47.2M | Buy |
612,554
+1,757
| +0.3% | +$129K | 0.12% | 144 |
|
|
2024
Q1 | $41.8M | Buy |
610,797
+15,660
| +3% | +$1.01M | 0.1% | 163 |
|
|
2023
Q4 | $34.4M | Buy |
595,137
+22,175
| +4% | +$1.18M | 0.1% | 175 |
|
|
2023
Q3 | $30.3M | Buy |
572,962
+33,133
| +6% | +$1.74M | 0.1% | 180 |
|
|
2023
Q2 | $29.2M | Buy |
539,829
+32,825
| +6% | +$1.71M | 0.09% | 177 |
|
|
2023
Q1 | $25.4M | Sell |
507,004
-4,475
| -0.9% | -$211K | 0.1% | 169 |
|
|
2022
Q4 | $23.7M | Buy |
511,479
+5,263
| +1% | +$228K | 0.11% | 170 |
|
|
2022
Q3 | $19.6M | Sell |
506,216
-3,802
| -0.7% | -$153K | 0.1% | 175 |
|
|
2022
Q2 | $19M | Buy |
510,018
+9,592
| +2% | +$390K | 0.09% | 195 |
|
|
2022
Q1 | $22.2M | Buy |
500,426
+31,391
| +7% | +$1.36M | 0.09% | 190 |
|
|
2021
Q4 | $19.9M | Sell |
469,035
-29,482
| -6% | -$1.24M | 0.07% | 211 |
|
|
2021
Q3 | $21.6M | Sell |
498,517
-36,218
| -7% | -$1.6M | 0.09% | 193 |
|
|
2021
Q2 | $22.9M | Hold |
534,735
| – | – | 0.09% | 188 |
|
|
2021
Q1 | $20.7M | Buy |
534,735
+15,922
| +3% | +$603K | 0.09% | 194 |
|
|
2020
Q4 | $18.6M | Sell |
518,813
-5,776
| -1% | -$208K | 0.1% | 190 |
|
|
2020
Q3 | $19.8M | Sell |
524,589
-2,212
| -0.4% | -$85.2K | 0.12% | 155 |
|
|
2020
Q2 | $18.3M | Sell |
526,801
-14,758
| -3% | -$531K | 0.13% | 156 |
|
|
2020
Q1 | $17.1M | Sell |
541,559
-10,483
| -2% | -$410K | 0.14% | 153 |
|
|
2019
Q4 | $24.8M | Buy |
552,042
+8,652
| +2% | +$362K | 0.17% | 134 |
|
|
2019
Q3 | $22.1M | Buy |
543,390
+14,043
| +3% | +$595K | 0.17% | 137 |
|
|
2019
Q2 | $22.7M | Sell |
529,347
-34,079
| -6% | -$1.31M | 0.22% | 110 |
|
|
2019
Q1 | $21.6M | Sell |
563,426
-28,825
| -5% | -$1.1M | 0.17% | 135 |
|
|
2018
Q4 | $20.5M | Buy |
+592,251
| New | +$21.5M | 0.18% | 126 |
|
|
2018
Q3 | – | Sell |
-575,800
| Closed | -$18.8M | – | 530 |
|
|
2018
Q2 | $18.8M | Buy |
+575,800
| New | +$17.4M | 0.19% | 119 |
|
|
2016
Q2 | $10.5M | Sell |
450,883
-5,676,184
| -93% | -$123M | 0.17% | 131 |
|
|
2016
Q1 | $325K | Buy |
6,127,067
+5,647,764
| +1,178% | +$99.2M | 0.47% | 41 |
|
|
2015
Q4 | $8.91M | Buy |
479,303
+192
| +0% | +$3.44K | 0.14% | 161 |
|
|
2015
Q3 | $7.86M | Buy |
+479,111
| New | +$8.19M | 0.13% | 177 |
|
|
2014
Q4 | $56.7K | Buy |
424,226
+97,923
| +30% | +$1.25M | 0.11% | 216 |
|
|
2014
Q3 | $3.89M | Buy |
326,303
+13,646
| +4% | +$172K | 0.1% | 228 |
|
|
2014
Q2 | $4.02M | Sell |
312,657
-1,579
| -0.5% | -$20.5K | 0.09% | 238 |
|
|
2014
Q1 | $4.06M | Sell |
314,236
-13,888
| -4% | -$182K | 0.09% | 233 |
|
|
2013
Q4 | $4.3M | Buy |
328,124
+2,252
| +0.7% | +$26.6K | 0.11% | 207 |
|
|
2013
Q3 | $3.76M | Hold |
325,872
| – | – | 0.1% | 232 |
|
|
2013
Q2 | $3.01M | Buy |
+325,872
| New | +$2.76M | 0.09% | 266 |
|
Other funds holding BSX
Royal London Asset Management's BSX Position: Q2 2026 in Review
Royal London Asset Management increased its Boston Scientific (BSX) stake by 13% in Q2 2026, buying an estimated $4.73M and bringing the position to 753,076 shares worth $32.1M. The position accounts for 0.06% of the portfolio, ranked #251.
Royal London Asset Management first reported a position in BSX in Q2 2013 and has held it in 43 quarters since. The position peaked at $74.1M in Q2 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Royal London Asset Management held 753,076 shares of Boston Scientific worth $32.1M as of Q2 2026.
- Royal London Asset Management bought 87,185 Boston Scientific shares in Q2 2026, an estimated $4.73M.
- Boston Scientific made up 0.06% of Royal London Asset Management's portfolio in Q2 2026, its #251 holding.
- Royal London Asset Management first reported a position in Boston Scientific in Q2 2013 and has held it in 43 quarters since.
- Royal London Asset Management's Boston Scientific position peaked at $74.1M in Q2 2025.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.